KPV: Anti-Inflammatory Tripeptide Research Guide
By UK Peptide Lab Research Team•22 May 2026•6 min read
What is KPV?
KPV is a tripeptide with the sequence lysine-proline-valine, corresponding to the C-terminal three amino acids (positions 11-13) of alpha-melanocyte-stimulating hormone (α-MSH). Despite its minimal size, KPV retains a substantial portion of the anti-inflammatory activity of the much larger parent peptide, making it a useful research tool for studies on melanocortin-derived anti-inflammatory signalling in models of gastrointestinal and dermatological inflammation.
UK Peptide Lab supplies KPV as research-grade lyophilised powder for in-vitro laboratory use only.
Derivation from Alpha-MSH
Alpha-MSH is a 13-amino-acid peptide hormone derived from the post-translational cleavage of pro-opiomelanocortin (POMC). In addition to its well-known role in melanogenesis through MC1R activation, α-MSH has documented anti-inflammatory activity in numerous research models, mediated through multiple receptors including MC1R, MC3R, and MC5R. The C-terminal tripeptide α-MSH(11-13), or KPV, was identified as a minimal sequence that retains a substantial fraction of the parent peptide's anti-inflammatory effect without producing the melanogenic effects associated with the N-terminal sequence.
Mechanism: NF-κB Pathway Modulation
KPV research has focused on the peptide's ability to suppress activation of nuclear factor kappa B (NF-κB), a transcription factor that drives the expression of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. In cell culture models, KPV reduces NF-κB nuclear translocation and downstream cytokine expression in response to inflammatory stimuli.
The receptor through which this effect is mediated remains debated. Original models proposed MC1R-dependent signalling, but subsequent research has identified KPV activity in MC1R-deficient mice, suggesting a partially MC1R-independent mechanism that may involve direct intracellular targets or other melanocortin family receptors such as MC5R.
Kannengiesser and colleagues reported in Inflammatory Bowel Diseases in 2008 that KPV produced significant anti-inflammatory effects in two mouse models of colitis (dextran sodium sulfate colitis and CD45RB-high transfer colitis), and that the effects persisted in mice expressing a non-functional MC1R. This established KPV as a research tool with anti-inflammatory activity at least partially independent of classical melanocortin receptor signalling.
Research Applications in Gut Models
KPV has been studied most extensively in gastrointestinal inflammation research. Models of ulcerative colitis, Crohn's-like ileitis, and chemically induced colitis have been used to characterise the peptide's effects on epithelial barrier integrity, mucosal cytokine expression, and inflammatory cell infiltration. The peptide is small enough to be considered for oral delivery research, which has driven interest in formulation approaches such as nanoparticle encapsulation.
Xiao and colleagues reported in Molecular Therapy in 2017 on a hyaluronic-acid-functionalised nanoparticle system for targeted oral delivery of KPV in ulcerative colitis research models, demonstrating reduced TNF-α expression and improved mucosal healing in treated animals compared with controls. This line of research illustrates the peptide's positioning within the broader 'gut peptide' research literature, where it is frequently grouped with BPC-157 and other compounds studied in gastrointestinal tissue models.
Comparison with BPC-157
KPV and BPC-157 are both small peptides studied in gastrointestinal research models, but they act through different proposed mechanisms. BPC-157 research focuses on angiogenesis, nitric oxide signalling, and growth-factor-related repair pathways. KPV research focuses on direct anti-inflammatory cytokine suppression through NF-κB modulation. The two are sometimes studied together in models examining both inflammation suppression and tissue repair. See the BPC-157 research guide and the BPC-157 and TB-500 research overview for context on related gut and tissue peptide research.
Laboratory Handling
KPV is supplied as lyophilised powder. Store at -20°C prior to reconstitution. Reconstitute with bacteriostatic water by slowly injecting the diluent down the inner wall of the vial and swirling gently. The tripeptide is relatively stable due to its small size and lack of disulphide bonds or labile residues, but should still be handled under sterile conditions. Store the reconstituted solution at 2-8°C and use within 4 weeks.
Sourcing in the UK
UK Peptide Lab supplies research-grade KPV as lyophilised powder with full third-party HPLC documentation published on the product page. Same-day UK dispatch on orders placed before 2pm GMT, free Royal Mail Tracked shipping over £45. For in-vitro laboratory research use only, not for human consumption.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. UK Peptide Lab products are not for human consumption and are sold strictly for laboratory research use only.